Expert Douglas Sborov, MD, MS, presents the case of a 54-year-old woman with newly diagnosed multiple myeloma and provides clinical insights on treatment.
EP. 1: Patient Profile: A 54-Year-Old Woman with Newly Diagnosed Multiple Myeloma
Douglas W. Sborov, MD, MS, provides a summary of the key details of the 54-year-old patient's medical history and multiple myeloma diagnosis.
EP. 2: Overview of Results from the DETERMINATION Trial of RVd plus ASCT for Newly Diagnosed Multiple Myeloma
A review of the recent findings from this clinical trial examining lenalidomide, bortezomib and dexamethasone plus autologous stem cell transplant for newly diagnosed multiple myeloma.
EP. 3: Discussion of Final Analysis of the GRIFFIN Study Comparing DARA+RVd versus RVd
Discussion of the final data analysis comparing daratumumab plus lenalidomide, bortezomib and dexamethasone to lenalidomide, bortezomib and dexamethasone alone.
EP. 4: Review of Primary Outcomes from the PERSEUS Trial of Subcutaneous DARA+VRd in Transplant-Eligible Newly Diagnosed Multiple Myeloma
Review of the key primary outcome data from this trial of subcutaneous daratumumab with bortezomib, lenalidomide and dexamethasone for newly diagnosed transplant eligible multiple myeloma patients.
EP. 5: Overview of the IsKia Trial Results Evaluating Isatuximab + KRd in Transplant-Eligible Newly Diagnosed Multiple Myeloma
Overview of findings from this phase 3 study evaluating isatuximab added to carfilzomib, lenalidomide and dexamethasone.
EP. 6: Summary of Final Analysis from the MASTER Trial of DARA+KRd
Review of the final analysis of data from the MASTER clinical trial assessing daratumumab plus carfilzomib, lenalidomide and dexamethasone.
EP. 7: Discussion of Phase 2 IFM 2018-04 Study Data Presented at 2023 ASH Examining DARA+VTd with Tandem ASCT for High Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma
Summary of findings presented at the 2023 ASH meeting from this phase 2 trial using daratumumab, bortezomib, thalidomide and dexamethasone with tandem autologous stem cell transplant in high risk newly diagnosed multiple myeloma patients.
EP. 8: Key Clinical Insights for the Management of Newly Diagnosed Multiple Myeloma
Practical insights for the management of patients with NDMM.
2 Commerce Drive Cranbury, NJ 08512